Ensysce Biosciences (ENSC) EBITDA (2018 - 2025)

Ensysce Biosciences (ENSC) has reported EBITDA for 8 consecutive years, with -$3.7 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, EBITDA fell 680.24% year-over-year to -$3.7 million in Q3 2025; TTM through Sep 2025 was -$11.0 million, a 74.91% decrease from a year earlier, with the FY2024 full-year figure at -$6.7 million, up 37.21% from the prior year.
• EBITDA was -$3.7 million for Q3 2025 at Ensysce Biosciences, down from -$1.8 million in the prior quarter.
• Over five years, EBITDA peaked at $644746.0 in Q3 2024 and troughed at -$16.9 million in Q3 2021.
• A 5-year average of -$3.6 million and a median of -$2.6 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 4071.91% in 2021 and soared 123.81% in 2024, its largest moves.
• Over 5 years, EBITDA stood at -$2.0 million in 2021, then sank by 209.0% to -$6.2 million in 2022, then surged by 49.11% to -$3.2 million in 2023, then declined by 13.33% to -$3.6 million in 2024, then slipped by 4.6% to -$3.7 million in 2025.
• The last three EBITDA figures came in at -$3.7 million (Q3 2025), -$1.8 million (Q2 2025), and -$2.0 million (Q1 2025), per Business Quant data.